Mitos Therapeutics develops mitochondrial-based anti-metabolic cancer drugs that target energy imbalances in patients. By restoring cellular homeostasis, the company aims to enhance health outcomes for cancer patients and improve their overall well-being.
Funding
$400K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer cells often exhibit metabolic abnormalities, including dysfunctional mitochondria, leading to energy imbalances that promote tumor growth and resistance to conventional therapies. Current cancer treatments do not directly address these underlying metabolic vulnerabilities.
Solution
Mitos Therapeutics is developing a new class of anti-cancer drugs that target mitochondrial metabolism to restore cellular homeostasis. Their approach aims to correct energy imbalances within cancer cells, disrupting their growth and potentially increasing their sensitivity to existing treatments. By specifically targeting metabolic dysregulation, Mitos Therapeutics seeks to offer a more effective and targeted approach to cancer therapy.
Target Audience
The primary target audience includes cancer patients, oncologists, and researchers focused on developing novel cancer treatments.
Features
- Development of small molecule therapeutics targeting mitochondrial function in cancer cells
- Focus on restoring cellular energy balance and disrupting tumor metabolism
- Aims to enhance the efficacy of existing cancer therapies by addressing metabolic resistance mechanisms